Can an existing skin drug heal rare, painful wounds?
NCT ID NCT07767864
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This study tests whether bimekizumab, a drug already approved for other skin conditions, can help heal wounds in people with pyoderma gangrenosum (PG), a rare and painful skin disorder. Adults with PG will receive injections of bimekizumab every few weeks for 24 weeks. The main goal is to see if the drug leads to significant wound healing, which could offer a new treatment option for this challenging condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bimekizumab, an experimental drug given as an injection under the skin
- What this could lead to
- If successful, this could point toward a new treatment option for pyoderma gangrenosum, a painful skin condition with few effective therapies.
- What could go wrong
- This is a small, early-phase study with only 15 participants, so results may not apply broadly. The drug is not yet approved for this condition and may cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PYODERMA GANGRENOSUM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Oregon Health & Science University, Department of Dermatology
Portland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New hope for painful skin ulcers: experimental drug enters human trials
- Can a psoriasis drug heal these stubborn skin ulcers?
- New injection aims to heal skin ulcers in rare disease
- Oxygen chamber therapy put to the test for dozens of diseases
- Promising drug trial for painful skin ulcers halted early
- New wound therapy for rare skin disease shows early promise